Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin

Erik Fung, MB, ChB, PhD1,2 Nikolaos A. Patsopoulos, MD, PhD3,4,5 Steven M. Belknap, MD6
Daniel J. O’Rourke, MD1,2,7 John F. Robb, MD1,2 Jeffrey L. Anderson, MD8,9
Nicholas W. Shworak, MD, PhD1,2,10 Jason H. Moore, PhD2,11,12

1 Section of Cardiology, Heart & Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
2 Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire
3 Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
4 Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
5 Broad Institute of Harvard and MIT, Cambridge, Massachusetts
6 Department of Medicine, Northwestern Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois
7 Section of Cardiology, Veterans Affairs Medical Center, White River Junction, Vermont
8 Cardiovascular Department, Intermountain Medical Center, Murray, Utah
9 University of Utah School of Medicine, Salt Lake City, Utah
10 Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire
11 Institute of Quantitative Biomedical Science, Dartmouth College, Hanover, New Hampshire
12 Departments of Genetics and Community and Family Medicine, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire

Address for correspondence and reprint requests Erik Fung, MB, ChB, PhD, Section of Cardiology, Heart & Vascular Center, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire 03756 (e-mail: erik.fung@hitchcock.org).


The publisher regrets an error in a sentence in the above article in Seminars in Thrombosis & Hemostasis, Volume 38, Number 8, p. 900. The correct sentence is as below:

In the latest prospective, clinical effectiveness trial, pharmacogenetic guidance was found to decrease the OOR INR by 12%.17